Measurement of caffeine and five of the major metabolites in urine by high-performance liquid chromatography/tandem mass spectrometry

Journal of Mass Spectrometry

Volumn 40, Issue 3, 2005, Pages 307-316

  Weimann, Allan ^a   Sabroe, Mads ^a   Poulsen, Henrik E ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Caffeine; Electrospray; Metabolites; Urine

Indexed keywords

BODY FLUIDS; CENTRIFUGATION; DRUG PRODUCTS; ENZYME KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; ULTRAVIOLET RADIATION;

5-ACETYLAMINO-6-AMINO-3-METHYLURACIL (AAMU); CAFFEINE; DETECTION LIMITS; DILUTION;

METABOLITES;

1 METHYLURIC ACID; 1 METHYLXANTHINE; 1,7 DIMETHYLURIC ACID; 5 ACETAMIDO 6 AMINO 3 METHYLURACIL; 5 ACETAMIDO 6 FORMYLAMINO 3 METHYLURACIL; CAFFEINE; DRUG METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; AUTOMATION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VIVO STUDY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY; ULTRAVIOLET RADIATION; URINALYSIS;

CAFFEINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MOLECULAR STRUCTURE; REFERENCE STANDARDS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 15344350177     PISSN: 10765174     EISSN: None     Source Type: Journal    
DOI: 10.1002/jms.785     Document Type: Article

References (41)

1. Poulsen HE, Loft S. Antipyrine as a model drug to study hepatic drug-metabolizing capacity. J. Hepatol. 1988; 6: 374.
2. Poulsen HE, Loft S. Early biochemical markers of effects: enzyme induction, oncogene activation and markers of oxidative damage. Toxicology 1995; 101: 55.
3. Poulsen HE. One sample antipyrine clearance after 90% partial hepatectomy in the rat. Liver 1985; 5: 200.
4. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 1993; 45: 1211.
5. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br. J. Clin. Pharmacol. 1984; 17: 459.
6. Kalow W. The use of caffeine for enzyme assays: a critical appraisal. Clin. Pharmacol. Ther. 1993; 53: 503.
7. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A1 and xanthine oxidase activities. Clin. Pharmacol. Ther. 1991; 50: 508.
8. Tang BK, Kadar D, Iriah J, Yip J, Kalow W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin. Pharmacol. Ther. 1991; 49: 648.
9. Nelson DR, Kamataki T, Vaxman DJ, Estabrook RW, Feyereisen R, Gonzales FJ, Coon MJ, Gunsalus IC, Gotoh O, Okuda K, Nebert D. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA Cell Biol. 1993; 12: 1.
10. Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol. Sci. 1992; 13: 346.
11. Mitchell JR, Thorgeirsson SS, Potter WZ, Jollow DJ, Kaiser H. Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin. Pharmacol. Ther. 1974; 16: 676.
12. Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 1992; 13: 1561.
13. Baud-Camus F, Marquet P, Soursac M, Davrinche C, Farinotti R. Determination of N-acetylation phenotype using caffeine as a metabolic probe and high-performance liquid chromatography with either ultraviolet detection or electrospray mass spectrometry. J. Chromatogr. B 2001; 760: 55.
14. Schänzer W, Thevis M, Opfermann G, Krug O. Electrospray ionization mass spectrometric characterization and quantitation of xanthine derivatives using isotopically labelled analogues: an application for equine doping control analysis. Rapid Commun. Mass Spectrum. 2004; 18: 1553.
15. 13C-caffeine metabolites by liquid chromatography-mass spectrometry: the use of metabolic ratios to assess CYP1A2 activity. J. Pharm. Biomed. Anal. 2004; 34: 379.
16. Schneider H, Ma L, Glatt H. Extractionless method for the determination of urinary caffeine metabolites using high-performance liquid chromatography coupled with tandem mass spectrometry. J. Chromatogr. B 2003; 789: 227.
17. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996; 6: 121.
18. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin. Pharmacol. Ther. 1987; 42: 157.
19. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin. Pharmacol. Ther. 1983; 33: 591.
20. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br. J. Clin. Pharmacol. 1984; 17: 459.
21. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin. Pharmacol. Ther. 1991; 49: 648.
22. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450pA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. USA 1989; 86: 7696.
23. Campbell ME, Grant DM, Inaba T, Kalow W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab. Dispos. 1987; 15: 237.
24. Grant DM, Tang BK, Campbell ME, Kalow W. Effect of allopurinol on caffeine disposition in man. Br. J. Clin. Pharmacol. 1986; 21: 454.
25. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin. Pharmacol. Ther. 1991; 50: 508.
26. Kalow W, Tang BK. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin. Pharmacol. Ther. 1991; 49: 44.
27. Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 1992; 13: 1561.
28. Lu JF, Cao XM, Yi T, Zhuo HT, Ling SS. Simultaneous determination of five caffeine metabolites in human urine with reverse-phase HPLC method. Anal. Lett. 1998; 31: 613.
29. Krul C, Hageman G. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. J. Chromatogr. B 1998; 709: 27.
30. Miceli JN, Chapman W. Measurement of caffeine metabolites in urine using diode-array detection HPLC. J. Liq. Chromatogr. 1990; 13: 2239.
31. Bendriss E, Markoglou N, Wainer IW. Liquid Chromatographic method for the simultaneous determination of caffeine and fourteen caffeine metabolites in urine. J. Chromatogr. B 2000; 746: 331.
32. Georga KA, Samanidou VF, Papadoyannis IN. Use of novel solid-phase extraction sorbent materials for high-performance liquid chromatography quantitation of caffeine metabolism products methylxanthines and methyluric acids in samples of biological origin. J. Chromatogr. B 2001; 759: 209.
33. Dobrocky P, Bennett PN, Notarianni LJ. Rapid method for the routine determination of caffeine and its metabolites by high-performance liquid chromatography. J. Chromatogr. B 1994; 652: 104.
34. Di Pietro MC, Vannoni D, Leoncini R, Liso G, Guerranti R, Marinello E. Determination of urinary methylated purine pattern by high-performance liquid chromatography. J. Chromatogr. B 2001; 751: 87.
35. Ullrich D, Compagnone D, Münch B, Brandes A, Hille H, Bircher J. Urinary caffeine metabolites in man. Eur. J. Clin. Pharmacol. 1992; 43: 167.
36. Wong P, Villeneuve G, Tessier V, Banerjee K, Nedev H, Jean-Claude BJ, Leyland-Jones B. Stability of 5-acetamido-6-formylamino-3-methyluracil in buffers and urine. J. Pharm. Biomed. Anal. 2003; 28: 693.
37. Röhrkasten R, Raatz P, Kreher RP, Blaszkewicz M. Synthesis of the caffeine metabolites 5-acetylamino-6-formylamino-3-methyluracil (AFMU) and 5-acetylamino-6-amino-3-methyluracil (AAMU) on a preparative scale. Z. Naturforsch., Teil B 1997; 52: 1526.
38. Johnson EA. The occurrence of substituted uric acids in human urine. Biochem. J. 1952; 51: 133.
39. Pfleiderer W. Synthese, Struktur und Eigenschaften der Harnsäure sowie ihrer N-Methylderivate. Justus Liebigs Ann. Chem. 1974; 2: 2030.
40. Raznoshinskii AI, Shcherbo NS, Yuzhakov VI. The electronic structure and spectral-luminescent properties of various methylated purines. Russ. J. Phys. Chem. 1990; 64: 674.
41. Fujii T, Saito T, Tamura K. Purines. XLIX. Synthesis and proton nuclear magnetic resonance study of 3,7-dialkylxanthines and 1,3,7-trialkylxanthines. Chem. Pharm. Bull. 2001; 39: 2855.